Tax share withholdings for Fulgent Genetics (NASDAQ: FLGT) COO

Rhea-AI Filing Summary

Fulgent Genetics President and COO Jian Xie reported several tax-related share withholdings of company common stock. On February 26, 2026, 1,140 shares were disposed of at $24.7600 per share to cover tax obligations from vesting restricted stock units. On March 1, 2026, additional tax-withholding dispositions of 1,079 and 8,147 shares occurred at $15.3300 per share. After these transactions, his direct holdings were reported as 375,313 shares of common stock. Separately, 220,816 shares are held indirectly by The Hsieh Family Dynasty Trust, for which Mr. Xie serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Xie Jian

Role President and COO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,079	$15.33	$17K
Tax Withholding	Common Stock	8,147	$15.33	$125K
Tax Withholding	Common Stock	1,140	$24.76	$28K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 383,460 shares (Direct); Common Stock — 220,816 shares (Indirect, By Trust)

Footnotes (1)

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xie Jian

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/26/2026		F		1,140(1)	D	$24.76	384,539	D
Common Stock	03/01/2026		F		1,079(2)	D	$15.33	383,460	D
Common Stock	03/01/2026		F		8,147(3)	D	$15.33	375,313	D
Common Stock								220,816	I	By Trust(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.

2. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022.

3. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.

4. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.

	/s/ Paul Kim as Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Fulgent Genetics (FLGT) President and COO Jian Xie report?

Jian Xie reported tax-withholding dispositions of Fulgent Genetics common stock, not open-market trades. Shares were withheld to cover tax obligations arising from vested restricted stock units, with multiple small blocks disposed at prices of $24.7600 and $15.3300 per share.

Were Jian Xie’s Fulgent Genetics (FLGT) Form 4 transactions open-market sales?

No, the Form 4 shows tax-withholding dispositions, not open-market sales. Shares were withheld by the company to satisfy tax liabilities when restricted stock units vested, as indicated by transaction code F and the accompanying tax-withholding footnotes.

How many Fulgent Genetics (FLGT) shares were disposed of for tax withholding by Jian Xie?

The filing reports three tax-withholding blocks: 1,140 shares at $24.7600 on February 26, 2026, and 1,079 plus 8,147 shares at $15.3300 on March 1, 2026, all to satisfy tax obligations from restricted stock unit vesting.

What are Jian Xie’s direct share holdings in Fulgent Genetics (FLGT) after these transactions?

After the reported tax-withholding dispositions, Jian Xie’s direct ownership in Fulgent Genetics common stock is listed as 375,313 shares. This figure reflects his remaining directly held shares following the withholding of stock to cover vesting-related tax liabilities.

What is the role of The Hsieh Family Dynasty Trust in Fulgent Genetics (FLGT) holdings?

The Form 4 shows 220,816 Fulgent Genetics shares held by The Hsieh Family Dynasty Trust. Jian Xie serves on the trust’s investment committee and disclaims beneficial ownership of these shares, except with respect to any pecuniary interest he may have.

What do the tax-withholding footnotes on Jian Xie’s Fulgent Genetics (FLGT) Form 4 explain?

The footnotes explain that shares were withheld to cover tax obligations from restricted stock units granted on specific past dates. Each disposition corresponds to vesting of earlier RSU awards that had been previously reported in earlier Form 4 filings.